The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Idiopathic pulmonary fibrosis (IPF), a lethal respiratory disease with few treatment options, occurs due to repetitive microinjuries to alveolar epithelial cells (AECs) and progresses with an overwhelming deposition of extracellular matrix (ECM), ultimately resulting in fibrotic scars and destroyed the alveolar architecture. Here, an inhaled ribosomal protein‐based mRNA nanoformulation is reported...
Nanomedicine
In article number 2107506, Xinyi Jiang and co‐workers introduce an inhaled nanoformulation that is developed with biogenic ribosomal protein for mRNA delivery. The variety of isoelectric points of ribosomal proteins endows them with flexible positive charge properties, by which negatively charged mRNA is efficiently condensed to form a nanocomplex in a biomimetic fashion.